Multidrug Resistance Protein 1 Inhibitors To Sensitise Cancers To Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$840,166.00
Summary
Multidrug resistance protein 1 (MRP1) is often present at high levels in cancer cells, where it pumps chemotherapy drugs back out, causing drug resistance. Inhibitors that block MRP1 would increase the effectiveness of chemotherapy. We have developed MRP1 inhibitors with promising activity in cancer cells and mouse tumours and will now develop these inhibitors for clinical application and commercialisation.
A Novel Liver Cancer Therapy Targeting Tumour Stroma
Funder
National Health and Medical Research Council
Funding Amount
$387,902.00
Summary
In Australia, there are 1,300 new cases of liver cancer each year with an average survival of 7 months. Liver cancer is now the most rapidly increasing cancer, probably caused by more hepatitis, obesity and diabetes. Our commercial partner has a novel innovative new antibody that shrinks other cancer types and we want to see how well it combats liver cancer in mice. This antibody has a raft of superior features and we have a clear plan towards making it available to patients.
Pharmacological Inhibitors Of Mnk For The Treatment Of Cancer
Funder
National Health and Medical Research Council
Funding Amount
$505,894.00
Summary
Cancer is a leading cause of death worldwide. In 2010 an estimated 43,000 Australians died from cancer and 114,000 new cases were diagnosed. New treatments are urgently needed. Protein kinases Mnks promote human tumourogenesis, but they are dispensable for normal tissue development. Inhibition of Mnks’ activity therefore presents an excellent strategy for effective and nontoxic cancer therapy. This project aims to develop Mnk inhibitor drug candidates for potential clinic application.